WO2004052933A3 - Peptide oligomers for use as hiv vaccines - Google Patents

Peptide oligomers for use as hiv vaccines Download PDF

Info

Publication number
WO2004052933A3
WO2004052933A3 PCT/GB2003/005436 GB0305436W WO2004052933A3 WO 2004052933 A3 WO2004052933 A3 WO 2004052933A3 GB 0305436 W GB0305436 W GB 0305436W WO 2004052933 A3 WO2004052933 A3 WO 2004052933A3
Authority
WO
WIPO (PCT)
Prior art keywords
neutralising
presentation
partially occluded
hiv
presentations
Prior art date
Application number
PCT/GB2003/005436
Other languages
French (fr)
Other versions
WO2004052933A2 (en
WO2004052933B1 (en
Inventor
Steven Paul Boneham
Jonathan Kelvin Ball
Original Assignee
Univ Nottingham
Steven Paul Boneham
Jonathan Kelvin Ball
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Nottingham, Steven Paul Boneham, Jonathan Kelvin Ball filed Critical Univ Nottingham
Priority to CA002509387A priority Critical patent/CA2509387A1/en
Priority to AU2003290260A priority patent/AU2003290260A1/en
Priority to US10/537,852 priority patent/US20060275309A1/en
Priority to EP03782624A priority patent/EP1576002A2/en
Publication of WO2004052933A2 publication Critical patent/WO2004052933A2/en
Publication of WO2004052933A3 publication Critical patent/WO2004052933A3/en
Publication of WO2004052933B1 publication Critical patent/WO2004052933B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Partially occluded and/ or multimeric presentations of peptides mimic the epitopes recognised by antibodies capable of neutralising diverse clinical isolates of the human immunodeficiency virus type 1 (HIV-1). By “partially occluded” is meant a presentation that has a three-dimensional structure (probably a barrel/cylindrical/ helical shape) generated by inter-chain disulphide bridging or other means that has internally, at or near its base, the epitope that is recognised by the neutralising antibody; i.e. a partially occluded presentation is a three-dimensional presentation of one or more neutralising epitopes such that the epitope is located in a pocket or cleft. Such presentations are better at eliciting antibodies that have the neutralising phenotype, and may be used as vaccines or to produce antibodies for the prevention or treatment of HIV-1 infection.
PCT/GB2003/005436 2002-12-12 2003-12-12 Peptide oligomers for use as hiv vaccines WO2004052933A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002509387A CA2509387A1 (en) 2002-12-12 2003-12-12 Peptide oligomers for use as hiv vaccines
AU2003290260A AU2003290260A1 (en) 2002-12-12 2003-12-12 Peptide oligomers for use as HIV vaccines
US10/537,852 US20060275309A1 (en) 2002-12-12 2003-12-12 Peptide oligomers for use as hiv vaccines
EP03782624A EP1576002A2 (en) 2002-12-12 2003-12-12 Peptide oligomers for use as hiv vaccines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0228939.5 2002-12-12
GBGB0228939.5A GB0228939D0 (en) 2002-12-12 2002-12-12 Peptide presentations for human immunodeficiency disease vaccines

Publications (3)

Publication Number Publication Date
WO2004052933A2 WO2004052933A2 (en) 2004-06-24
WO2004052933A3 true WO2004052933A3 (en) 2005-03-24
WO2004052933B1 WO2004052933B1 (en) 2005-05-06

Family

ID=9949530

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2003/005436 WO2004052933A2 (en) 2002-12-12 2003-12-12 Peptide oligomers for use as hiv vaccines

Country Status (6)

Country Link
US (1) US20060275309A1 (en)
EP (1) EP1576002A2 (en)
AU (1) AU2003290260A1 (en)
CA (1) CA2509387A1 (en)
GB (1) GB0228939D0 (en)
WO (1) WO2004052933A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004274494A1 (en) * 2003-09-19 2005-03-31 The Scripps Research Institute Peptide that binds to a broadly neutralizing anti-HIV antibody-structure of 4E10 FAB fragment complex, uses thereof, compositions therefrom
WO2006091455A2 (en) * 2005-02-18 2006-08-31 Uab Research Foundation Molecular scaffolds for hiv-1 immunogens
JPWO2007063807A1 (en) * 2005-11-29 2009-05-07 オリンパス株式会社 Analysis method of primary structure change of nucleic acid

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185147A (en) * 1988-08-19 1993-02-09 Cellular Products, Inc. Short polypeptide sequences useful in the production and detection of antibodies against human immunodeficiency virus
WO1994003487A1 (en) * 1992-08-10 1994-02-17 Neovacs New peptides, antibodies raised against peptides and means for blocking said antibodies, application as medicaments, pharmaceutical compositions and utilization methods
WO1994029339A1 (en) * 1993-06-09 1994-12-22 Connaught Laboratories Limited Tandem synthetic hiv-1 peptides
US5750332A (en) * 1994-01-19 1998-05-12 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Peptomers with enhanced immunogenicity
WO2003022879A2 (en) * 2001-09-07 2003-03-20 Polymun Scientific Immunbiologische Forschung Gmbh Peptides mimicking a cryptic epitope of gp41 hiv-1 and antibodies directed against them

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001019958A2 (en) * 1999-09-17 2001-03-22 Dana-Farber Cancer Institute, Inc. Stabilized soluble glycoprotein trimers
US7179468B1 (en) * 2000-06-08 2007-02-20 Cornell Research Foundation, Inc. Antigen for developing neutralizing antibodies to human immunodeficiency virus
JP2005502350A (en) * 2001-09-06 2005-01-27 プロジェニクス・ファーマスーティカルズ・インコーポレイテッド Human immunodeficiency virus envelope glycoprotein variants and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185147A (en) * 1988-08-19 1993-02-09 Cellular Products, Inc. Short polypeptide sequences useful in the production and detection of antibodies against human immunodeficiency virus
WO1994003487A1 (en) * 1992-08-10 1994-02-17 Neovacs New peptides, antibodies raised against peptides and means for blocking said antibodies, application as medicaments, pharmaceutical compositions and utilization methods
WO1994029339A1 (en) * 1993-06-09 1994-12-22 Connaught Laboratories Limited Tandem synthetic hiv-1 peptides
US5750332A (en) * 1994-01-19 1998-05-12 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Peptomers with enhanced immunogenicity
WO2003022879A2 (en) * 2001-09-07 2003-03-20 Polymun Scientific Immunbiologische Forschung Gmbh Peptides mimicking a cryptic epitope of gp41 hiv-1 and antibodies directed against them

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BIOCONJUGATE CHEMISTRY., vol. 15, 2004, USAMERICAN CHEMICAL SOCIETY, WASHINGTON., pages 112 - 120, XP002309578 *
JOURNAL OF IMMUNOLOGY., vol. 148, no. 12, 15 June 1992 (1992-06-15), USTHE WILLIAMS AND WILKINS CO. BALTIMORE., pages 4012 - 4020, XP002309573 *
JOURNAL OF IMMUNOLOGY., vol. 162, no. 10, 15 May 1999 (1999-05-15), USTHE WILLIAMS AND WILKINS CO. BALTIMORE., pages 6155 - 6161, XP002309574 *
JOURNAL OF VIROLOGY., vol. 75, no. 12, June 2001 (2001-06-01), USTHE AMERICAN SOCIETY FOR MICROBIOLOGY., pages 5526 - 5540, XP002309575 *
JOURNAL OF VIROLOGY., vol. 75, no. 14, July 2001 (2001-07-01), USTHE AMERICAN SOCIETY FOR MICROBIOLOGY., pages 6692 - 6699, XP002309577 *
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA., vol. 89, May 1992 (1992-05-01), USNATIONAL ACADEMY OF SCIENCE. WASHINGTON., pages 3879 - 3883, XP002309576 *

Also Published As

Publication number Publication date
GB0228939D0 (en) 2003-01-15
CA2509387A1 (en) 2004-06-24
WO2004052933A2 (en) 2004-06-24
WO2004052933B1 (en) 2005-05-06
EP1576002A2 (en) 2005-09-21
US20060275309A1 (en) 2006-12-07
AU2003290260A1 (en) 2004-06-30

Similar Documents

Publication Publication Date Title
WO2001098333A3 (en) Modification of hepatitis b core antigen
CA2164818A1 (en) Tandem synthetic hiv-1 peptides
FR2627696B1 (en) NEW GALENIC FORM OF FENOFIBRATE
AU2001295673A1 (en) Vaccine composition
EA200200724A1 (en) VACCINE FOR PREVENTION OR THERAPEUTIC IMMUNIZATION AGAINST THE VIRUS OF HUMAN IMMUNODEFICIENCY (HIV)
HUP9901109A2 (en) Peptide immunogens for vaccination against and treatment of allergy
CY1111636T1 (en) Vaccine Containing GP120 And NEF KAI / TH TAT FOR Immunization Against HIV
WO2003028757A1 (en) Novel method of inducing antigen-specific t cells
HUP0202502A2 (en) Peptides that block viral infectivity and methods of use thereof
WO2006050219A3 (en) Broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies
WO2002077012A3 (en) Human papilloma virus immunoreative peptides
EP1762620A3 (en) Cryptosporidium parvum antigens, antibodies thereto and diagnostic and therapeutic compositions thereof
WO2002078631A3 (en) Improved conditionally replicating vectors for inhibiting viral infections
WO2004052933A3 (en) Peptide oligomers for use as hiv vaccines
WO2005037222A3 (en) Recombinant intracellular pathogen immunogenic compositions and methods for use
WO2018055535A3 (en) Hepatitis c virus immunogenic compositions and methods of use thereof
WO2006102098A3 (en) Immunogens for vaccines against antigenically variable pathogens and diseases
DE69636527D1 (en) ANTIGENE PROTEIN FROM MALASSEZIA
WO2012050893A3 (en) Immunogenic polypeptides having an immunogenic scaffold protein and a loop peptide, presenting a 3074- or 2219/2557- monoclonal antibody-targeted epitope, which is present in the hiv gp120 protein
EP1556081A4 (en) Recombinant intracellular pathogen immunogenic compositions and methods for use
WO2002069691A3 (en) Immunogenic hiv peptides for use as reagents and vaccines
DK1423525T3 (en) Recombinant MVA capable of expressing HCV structural antigens
WO2006027468A3 (en) Hla-dp4 restricted t cd4+ du vih epitopes and the use thereof
DE60210936D1 (en) POLYPEPTIDE THAT INDUCES NEUTRALIZING ANTIBODIES TO HIV
HUP0401121A2 (en) Modified thrombopoietin with reduced immunogenicity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
B Later publication of amended claims

Effective date: 20050223

WWE Wipo information: entry into national phase

Ref document number: 2003290260

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2509387

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003782624

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003782624

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006275309

Country of ref document: US

Ref document number: 10537852

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 10537852

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2003782624

Country of ref document: EP